BioSpace News Archive

Boston Pharmaceuticals today announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D., as Acting Chief Medical Officer (CMO).

Intelligent Bio Solutions Inc. today announced that it has received National Association of Testing Authorities (NATA) accreditation for its Intelligent Fingerprinting Drug Screening Solution.

SNP Therapeutics Inc announced today it is launching a line of prenatal nutrition products to complement its Genate™ Test, a prenatal genetic screening test. Genate Prenatal Nutrition will enable women to optimize their nutrition plan based on gene variants associated with nutrient metabolism.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB).

Treace Medical Concepts, Inc. today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.

BioCryst Pharmaceuticals, Inc. announced that data from the open-label extension of the APeX-2 trial of oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema in patients 12 years and older have been published online by the Journal of Allergy and Clinical Immunology: In Practice.

BioCardia ® , Inc. today announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF).

Tiziana Life Sciences Ltd. today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).

LTS, a leading pharmaceutical technology company, announced that it has received a grant from the Bill & Melinda Gates Foundation.

GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, announced a new partnership with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.